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Introduction. This study was designed to identify the delays and factors related to and predicting the cessation of generalized
convulsive SE (GCSE). Methods. This retrospective study includes 70 consecutive patients (>16 years) diagnosed with GCSE and
treated in the emergency department of a tertiary hospital over 2 years. We defined cessation of SE stepwise using clinical seizure
freedom, achievement of burst-suppression, and return of consciousness as endpoints and calculated delays for these cessation
markers. In addition 10 treatment delay parameters and 7 prognostic and GCSE episode related factors were defined. Multiple
statistical analyses were performed on their relation to cessation markers. Results. Onset-to-second-stage-medication (𝑝 = 0.027),
onset-to-burst-suppression (𝑝 = 0.005), and onset-to-clinical-seizure-freedom (𝑝 = 0.035) delays correlated with the onset-to-
consciousness delay. We detected no correlation between age, epilepsy, STESS, prestatus period, type of SE onset, effect of the
first medication, and cessation of SE. Conclusion. Our study demonstrates that rapid administration of second-stage medication
and early obtainment of clinical seizure freedom and burst-suppression predict early return of consciousness, an unambiguous
marker for the end of SE. We propose that delays in treatment chain may be more significant determinants of SE cessation than the
previously established outcome predictors. Thus, streamlining the treatment chain is advocated.
1. Introduction
Status epilepticus (SE) is a common and life-threatening con-
dition, which requires urgent medical attention. The inci-
dence of SE ranges from 10 to 20 per 100 000 [1] and gen-
eralized convulsive SE (GCSE) is by far the most common
subtype. SE causes permanent brain damage especially in
the hippocampal area [2] and permanently lowers seizure
threshold predisposing to epilepsy [3]. Prolonged seizures
respond poorly to treatment due to GABA-receptor traffick-
ing occurring along the progressive SE episode [4].
Mortality of SE varies greatly (1.9%–40.0%) in published
series [1]. Predictors of a poor outcome include age, structural
brain lesion, prolonged seizure, acute symptomatic convul-
sions, and certain EEG findings during and after SE [5–7].
SE may require treatment in intensive care unit (ICU), which
also increases mortality through treatment complications [5,
8]. Both brain damage andmortality are affected by longevity
of the seizure andmortality increases greatly after 30minutes
of seizing [9]. In a pediatric study, every minute of ongoing
seizure elevated the risk for a seizure prolongation over 60
minutes by five percent [10]. Permanent damage in SE is time-
dependent, and seizure duration is the only prognostic factor
that can be affected by rapid treatment [11].
It has been recently shown that delays in the treatment of
SE are unacceptably long [12]. The effect of treatment delay
on prognosis of SE is controversial and subject to debate
in the literature. Most studies have focussed on the relation
between first-stage medication and outcome, indicated by
mortality, patient’s condition at discharge and its return to
baseline, or by clinical scales. Some studies found that a
treatment delay has a clear impact on prognosis; the longer
the delay, the worse the outcome [6, 13–15]. A few studies
suggested that the treatment delay per se plays an important
role on the prognosis besides the etiology [16–18]. Still there
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are opposite results suggesting that a long treatment delay
does not correlate with higher mortality [19–22], and con-
sequently the prognosis of SE is mainly determined by its
biological background [23] and affected by its refractoriness
[22]. This controversy may partly be explained by the recent
observation that, regardless of the adequately started pre-
hospital initial treatment, the delays in consecutive parts of
the treatment chain were far from optimal [24].
Treatment of SE is guided by two international guide-
lines [25, 26]. Adherence to treatment protocol, quality of
treatment, and management within the recommended time
frames seem to have a significant impact on the prognosis
of SE [27–29]. Still a recently published study suggested that
treatment latency and adherence to protocol were not related
to outcome of SE [30].
SE is a very dynamic process with diagnostic challenges,
several treatment stages, and potential misinterpretations
over the whole management process. Systematic analysis of
the factors related to different parts of the treatment chain
is needed to draw definite conclusions on the impact of the
delays on prognosis. Our newly published study focussed on
factors related to delays in the pre-hospitalmanagement of SE
[24]. To our knowledge, there are no published studies inves-
tigating systematically the factors relating to the cessation of
SE.
This study was designed to identify the delays and factors
related to markers for cessation of GCSE and particularly to
identify factors predicting the return of consciousness after
GCSE. We also aim at validation of the stepwise definition
for the cessation of SE, published earlier [12].
2. Methods
2.1. Study Design and Setting. This is a retrospective cohort
study performed in Helsinki University Central Hospital
(HUCH), a tertiary hospital serving a population of 1.4 mil-
lion. HUCH provides neurological emergency service 24 h
a day for the hospital district. The local Emergency Medical
Service (EMS) has been instructed to transport patients with
GCSE primarily to HUCH Emergency Department (ED).
This study conforms to the Finnish legislation concerning
medical research and the permission was granted by the
HUCH Department of Neurology.
2.2. Selection of Participants. This study material includes
consecutive adult patients (over 16 years of age) diagnosed
with generalized convulsive status epilepticus (GCSE) and
treated in theHUCHEDover a two-year period from January
2002 till December 2003.
The patients were identified in the HUCH electronic
patient database by the ICD-10 code G41 (SE), yielding a
total of 87 patients. Established SE was defined as continuous
seizures lasting over 30 minutes, several recurrent seizures
without returning consciousness, or occurrence of more than
four seizures within any one hour irrespective of return of
consciousness in between. Patients not meeting these criteria
were excluded, despite having the SE diagnosis in their
records, resulting in a total of 82 patients.The seizure descrip-
tion was collected from original medical records for all these
patients. Patients having a convulsive seizure at any point of
the SE periodwere considered as having convulsive SE (CSE).
Patients with impaired consciousness, either primarily or
secondarily, were considered as having generalized SE (GSE).
Altogether 70 patients met the criteria for GCSE and were
included in this study.
2.3. Data Collection. A trained medical doctor collected the
data from the original medical records on a standard form
designed for this study. The records consisted of notes
made by nurses and doctors of EMS, health care centers,
regional hospitals, and HUCH ED, ICU, or neurological
ward. Ambiguous data were evaluated in collaboration with
the research team and if the consensus concerning the
original coding rules changed, the data in question were rec-
ollected.The electronic databasewas created usingMSAccess
for data recording. The information of patient identification
was removed before further analyses.TheWeightedAccuracy
Score 𝐿WAS and the Data Availability (DA) were calculated
for all time parameters, using the method developed for
evaluation of retrospective delay materials [12]. 𝐿WAS refers
to the deviation of the time parameters from the absolute
accuracy in the medical records. The data on delays were
based on events with exact time points documented in the
medical records, whenever possible. For events not accurately
documented, clinically grounded estimation of the event time
was based on time frames with exact documented time points
at each end.
2.4. Measures. Demographic data, medical history of the
cases, etiologic and predisposing factors of GCSE and
patients’ condition at HUCH discharge are presented in
Online Table 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2015/591279. Mortality was calcu-
lated over HUCH admission period. No postdischarge fol-
low-up was performed in this study.
We defined and calculated 13 parameters for delay in the
management of GCSE. All delays were counted from the
onset of GCSE. The time parameters and the median delays
are presented in Table 1.
We defined 7 grouping variables (prognostic factors and
GCSE episode parameters) for subgroup analysis. The vari-
ables are presented in Table 2.
Cases with events missing, for example, no burst-sup-
pression (BS) and events happening during prestatus period,
or with unknown data were excluded from the final analysis.
The missing data information is presented in Online Table 2.
The onset of GCSE was defined as the beginning of the
first seizure, fulfilling the criteria for establishedGCSE. Initial
treatment was defined as the first given antiepileptic drug
(AED), which was not necessarily the first-stage medication.
Alarm delay refers to the primary alarm, in this case the delay
in calling the ambulance.
Onset-to-first-convulsion-end refers to the time between
the onset of GCSE and the end of the first clinical convulsion.
The second-stage medication included i.v. fosphenytoin or
valproate, and the third-stagemedication included anesthesia
with intravenous (i.v.) propofol, thiopental, or midazolam.
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Table 1: Delay parameters and the delays in the management of GCSE.
Variable 𝑁 % Time Time MIN MAX DA 𝐿WASAll Cases 70 100 Median Mean %
Delays in the treatment
Onset-to-initial-treatment 67 95.7 30min 57min 0min 8 h 5min 97.0 1.8
Onset-to-alarm 60 85.7 36min 2 h 27min 0min 57 h 44min 93.3 1.5
Onset-to-first-convulsion-end 70 100 51min 2 h 13min 1min 63 h 40min 97.1 1.8
Onset-to-diagnosis 70 100 1 h 48min 4 h 6min 60 h 6min 97.1 1.5
Onset-to-second-stage-medication 67 95.7 2 h 40min 4 h 49min 30min 61 h 54min 98.5 1.6
Onset-to-anesthesia 62 88.6 2 h 38min 5 h 43min 0min 66 h 20min 98.4 1.5
Onset-to-first-ED 61 87.1 2 h 2min 3 h 31min 0min 58 h 29min 98.4 1.5
Onset-to-tertiary-hospital (HUCH) 70 100 2 h 25min 1 h 25min 37min 277 h 40min 98.6 1.5
Onset-to-EEG 57 81.4 21 h 52min 33 h 2 h 30min 142 h 94.7 1.5
Onset-to-EEG-monitoring 42 60.0 11 h 10min 15 h 45min 2 h 30min 82 h 14min 97.6 1.5
Delays in the markers for cessation of GCSE
Onset-to-burst-suppression 30 42.9 14 h 42min 25 h 20min 5 h 5min 137 h 50min 100.0 1.5
Onset-to-clinical-seizure-freedom 70 100 5 h 15min 31 h 5min 26min 533 h 15min 98.6 1.6
Onset-to-consciousness 61 87.1 42 h 45min 66 h 5min 2 h 40min 444 h 40min 96.7 1.4
Table 2: Grouping variables (prognostic factors and GCSE episode
parameters) for the subgroup analysis.
Variable 𝑁 %
All 70 100
Age under 65
Yes 51 72.9
No 19 27.1
Epilepsy
Yes 46 65.7
No 23 32.9
Unknown 1 1.4
STESS
2 35 50.0
3 16 22.9
4 10 14.3
5 9 12.9
Prestatus period
Yes 14 20.0
No 56 80.0
SE onset
Continuous 45 64.3
Intermittent 25 35.7
Effect of the first medication
Yes 17 24.3
No 39 55.7
Spontaneous cessation 11 15.7
Refractoriness
Non-RSE 8 11.4
RSE 30 42.9
SRSE 32 45.7
Induction was considered as the exact time point of anesthe-
sia. First ED was defined as the first emergency department
the patient was transported to. Tertiary hospital always refers
to HUCH ED.
We defined the markers for cessation of GCSE with three
separate parameters for the treatment response [12]: BS, clin-
ical seizure freedom and return of consciousness. BS refers to
the beginning of the first BS sequence during this SE. Clinical
seizure freedom refers to the end of the last clinical convul-
sion and return of consciousness refers to the time point,
when the patient no longer presented altered mental status.
Age of 65 years was selected as the classification basis
for age as a grouping variable. Only patients with previously
diagnosed epilepsy were considered as having epilepsy. Status
Epilepticus Severity Score (STESS) [21] was calculated for
all patients. Seizures occurring no more than 48 h prior to
GCSE onset were referred to as the prestatus period seizures.
Seizures lasting clinically at least 30min were defined as
continuous. All other types of seizures were considered as
intermittent. The patient was considered to respond to the
initial treatment, if the seizure stopped within 10min after
i.v. administration or 20min after rectal administration of the
first medication, with no other simultaneous AEDs. Patients
failing to respond to the first or second-stage treatment were
considered as having refractory SE (RSE). SE continuing or
recurring 24 h or more after the onset of anesthesia was
considered as super-refractory SE (SRSE).
2.5. Statistics. The results are expressed as mean/median and
range/interquartile range (IQR) or as number of patients and
percentage. The normality of variables was tested with the
Kolmogorov-Smirnov test. For the nonnormal data, the
Spearman’s correlation coefficient and, for normally distrib-
uted data, the Pearson’s correlation coefficient were calcu-
lated to find correlation between continuous variables. Boot-
strap resampling (1000 samples) was used to calculate the
bias corrected percentile confidence intervals for correla-
tion coefficients. Statistical significance of the differences in
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Figure 1: Kaplan-Meier curve showing the difference of the onset-
to-clinical-seizure-freedom time between patients returning con-
sciousness and remaining unconscious.
variables between independent samples was tested with the
nonparametric Wilcoxon-Mann–Whitney test. Differences
in categorical variables were examined using the Fisher’s
exact test. The Kaplan-Meier analysis with the log-rank test
was used to analyze time to event data. Linear regression
analysis with bootstrap resampling (5000 samples) was used
to model delays in treatment response. Statistical analyses
were executed using the SPSS software (version 22.0, SPSS,
IBM Corp. USA). Statistical significance was defined as 𝑝 <
0.05 and two tailed tests were used.
3. Results
The total-time-correlations, that is, correlations between the
onset-to-event and onset-to-treatment-response delays, that
is, markers for the cessation of SE, are shown in Table 3(a).
Since thismethod includes cumulative delays in the total time
fromonset to treatment response and thereforemay represent
inherent correlations, we also calculated the chronological
correlations, that is, correlations between the onset-to-event
and event-to-treatment-response delays, shown inTable 3(b).
Correlation significances given below are based on chrono-
logical correlation.
Regardless of the method of calculation, the delays in
giving the second-stage medication (𝑝 = 0.027), obtaining
the BS (𝑝 = 0.005) and achieving the clinical seizure freedom
(𝑝 = 0.035) correlate significantly with the delay in returning
of consciousness (Table 3(b)). 76.7% of the BSs were regis-
tered with EEG-monitoring before full scale EEG. Therefore,
the statistically significant negative correlation between full
scale EEG delay and BS delay is clinically insignificant.
Clinical seizure freedom delay among patients regaining
consciousness (𝑁 = 60, median 3.67 h, 95% CI = 1.64–5.69 h,
and DA = 98%, 𝐿WAS = 1.58) was significantly (𝑝 = 0.022)
shorter than that among patients remaining unconscious
(𝑁 = 9, median 41.17 h, 95% CI 14.87–67.46 h, DA = 100%,
and 𝐿WAS = 1.67) (Figure 1).
The difference in BS delay between patients regaining
consciousness (𝑁 = 22, median 12.0 h, 95% CI 9.32–
14.68 h, DA = 95%, and 𝐿WAS = 1.5) and those remaining
unconscious (𝑁 = 8, median 18.0 h, 95% CI 8.16–27.84 h, DA
= 100%, and 𝐿WAS = 1.5) did not reach statistical significance
(𝑝 = 0.398).
Out of the 70 GCSE cases, 30 cases (42.9%) obtained BS
and 40 cases (57.1%) did not. 42 cases (60.0%) of all cases had
EEG-monitoring and 30 cases (71.4%) of them obtained BS.
In the BS-group eight cases (26.7%) remained unconscious,
whereas in the non-BS-group one case (2.5%) remained
unconscious, the difference being statistically significant (𝑝 =
0.004). In the BS-group 23 cases (76.7%) and in the non-
BS-group nine cases (22.5%) fulfilled the criteria of SRSE,
the difference being statistically significant (𝑝 < 0.001).
The non-BS-group contained all the non-RSE cases of the
study material (8/70). Furthermore, in the BS-group all 30
cases were anesthetized with propofol, 20.0% of these cases
had multiple anesthetics and 36.7% had several anesthesia
periods, the median total anesthesia time being 59 hours 12
minutes (DA = 100%, 𝐿WAS = 1.48). In the non-BS group
all RSE and SRSE cases (32) were anesthetized with only one
anesthetic propofol. Four cases (12.5%) had several anesthesia
periods, the median total anesthesia time being 20 hours 20
minutes (DA = 97%, 𝐿WAS = 1.48).
Regression analysis was performed to reveal the cor-
relation of clinical variables with the delays in treatment
response.The time parameters having significant effect on the
delays of clinical seizure freedom or return of consciousness
are shown in Table 4. Regression analysis was not performed
on BS delays due to low number of patients (𝑁 = 30).
Univariate analysis of the factors related to markers for
cessation of GCSE is shown in Online Table 3. SRSE cases
have significantly longer delays in achieving clinical seizure
freedom and returning consciousness than non-SRSE cases
(𝑝 < 0.001).
Univariate analysis of the factors related to return of
consciousness is presented in Online Table 4. No significant
relations were found, although the non-SRSE cases tended to
regain consciousness more likely than the SRSE cases (𝑝 =
0.070).
In pooled STESS groups 0–2, 42.7% of the cases, and
in pooled STESS groups 3–6, 48.6% of the cases presented
SRSE. When STESS groups were pooled 0–3 and 4–6, the
proportion of cases presenting SRSE was 47.1% and 42.1%,
respectively.
4. Discussion
This is to our knowledge the first study analysing systemati-
cally the delays and factors related to cessation of GCSE. We
found that the earlier the clinical seizure freedom is achieved,
the earlier and more likely the consciousness returns. Delay
of clinical seizure freedom is significantly affected by several
delays in the preceding treatment chain. Short delays in giving
the second-stage medication and obtaining BS also correlate
with early return of consciousness. Surprisingly, several pre-
viously reported prognostic factors, such as age, epilepsy, or
STESS and the response to initial treatment are related neither
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Table 4: The regression analysis of the effect of the chronological delay components on markers for cessation on GCSE.
Variable TIME 95% CI 95% CI 𝑝
(h) min max
Onset-to-clinical-seizure-freedom
Intercept 9.0 −1.4 23.6 0.082
Onset-to-initial-treatment 7.8 −1.6 13.2 0.008
Initial-treatment-to-diagnosis 2.3 0.2 4.2 0.016
Intercept 8.2 −5.6 31.3 0.273
Onset-to-initial-treatment 6.6 −2.8 11.6 0.035
Initial-treatment-to-second-stage-medication 3.0 0.4 4.8 0.021
Onset-to-consciousness
Intercept 38.1 14.8 73.4 0.008
Onset-to-initial-treatment 0.4 −15.2 8.1 0.935
Initial-treatment-to-second-stage-medication 9.7 3.9 15.8 0.002
to the probability nor the delay of returning consciousness.
The present results suggest that the cessation of the GCSE
might be more likely related to the delays in the treatment
than to the known prognostic factors of SE outcome.
The risk for reporting bias is present in every retrospective
study. We controlled the risk by evaluating the adequacy of
the data with Data Accuracy (𝐿WAS) and Data Availability
(DA) scores using the method published recently [12]. The
scores in this study indicate that the accuracy and coverage
of patient data recordings seem to be on an adequate level.
We included only patients with GCSE in this study to assure
the uniformity of our material.
Although the patient material was collected in 2002-2003
in one tertiary hospital and is relatively small, it is comparable
to more recent materials since the treatment recommenda-
tions have not markedly changed during the past decade.The
increased assortment of intravenously administered second-
stage medications in the past years does not affect the inter-
pretation of our results. In this study fosphenytoinwas almost
exclusively administered as the second-stage medication,
providing a relatively homogeneous material. At the time of
collection of the material the EEG-monitoring availability
was insufficient. Still, the criteria for monitoring and the
interpretation of the results have not changed. Direct com-
parison of the present results to previously published studies
should be carried out with caution, since return of conscious-
ness is not widely used in the literature as the marker for
cessation of SE. Furthermore, definition of the duration of
SE varies considerably among previously published studies.
The most commonly used endpoint has been outcome, that
is, mortality and/or condition at discharge.
4.1. Relation of Delays to Cessation of SE. The exact endpoint
of SE is conceptually problematic and varies even in the
few previous studies that have clearly defined the endpoint.
Cessation of GCSE is defined by Rantsch et al. as the end of
the convulsion [22]. Absence of clinical seizure as the only
marker seems insufficient since 48% of the seizures continue
as electrographic SE [31]. Others have used a combination of
last clinical seizure and last continuous electrografic seizure
as the criteria without any specific time frames [32, 33].Mayer
et al. used additional time frame criteria, requiring the patient
to be seizure free for at least 72 h after the last clinical or
electrographic seizure [34]. SE is a dynamic process, and
therefore we have suggested a stepwise definition for cessa-
tion of SE, including time points of clinical seizure freedom,
obtaining BS and return of consciousness [12].This definition
was used in the present study, since return of consciousness
is the only reliable clinical marker for the end of GCSE.
Recent evidence indicates that the median delay in giving
the second-stage medication and the third-stage medication
is nearly the same [12, 24].The second-stagemedication delay
resulted mostly from lack of refrigerator in the ambulance
required for fosphenytoin storage [12], and in some cases
from failure in choosing an adequately specialized hospital
for treatment [24]. Two studies have combined fosphenytoin
with traditional first-stage treatment given out of hospital
[29, 35]. One of them [29] included doctor-ledmedical emer-
gency teams and the authors found that patients receiving
first long-acting AED according to the protocol (fospheny-
toin or lorazepam) were 19.9 times more likely to obtain
seizure termination (𝑝 < 0.0001) [29]. In the present study,
the delay in giving the second-stagemedication showed a sig-
nificant correlationwith the delay in returning consciousness.
These results together strongly suggest that the second-stage
medication should be available already in EMS units and be
administered together with the first-stage medication, pro-
vided that adequate physician evaluation of the patient can be
obtained to assure the correct diagnosis and the patient safety.
The evidence for the utility of BS as a goal in the treatment
ofGCSE is scarce andnoprospective studies are available.The
effect of BS on the prognosis of GCSE patients is controversial
[36]. Jaitly et al. found that the presence of BS, regardless of
SE etiology or the medication administered, was a sign of a
grave prognosis [37]. In another study seizure control without
suppression of electric activity to BS or isoelectric level
predicted good functional recovery [38]. A few studies have
reported that BS had no effect on treatment response or on
prognosis [32, 39]. Claassen et al. suggested that BS correlates
with favourable treatment response, but still its significance
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in predicting permanent absence of seizures, mortality, or
clinical recovery was questioned [40]. Usefulness of BS as
the goal of SE treatment has been advocated based on evi-
dence that the depth of EEG suppression correlates with
favourable outcome [41]. Nevertheless, maintenance of BS
for at least 24 h is recommended by the European guideline
[25], although, as the American guideline states, the EEG
endpoint of treatment is controversial, and there are no data
indicating as for what duration of treatment is sufficient to
obtain permanent seizure termination [26].
In our material the risk of remaining unconscious was
significantly higher among patients achieving BS than among
patients not treated to BS. The BS-group contained a sig-
nificantly higher proportion of SRSE cases than the non-BS
group. The BS-group also needed more often several anes-
thetizing agents and repeated anesthesia periods during the
total anesthesia time of nearly 40 h longer than that of the
non-BS-group.We also showed that the SRSE cases remained
unconscious more likely than the non-SRSE cases. We pro-
pose that it is not the BS itself that increases the risk of
remaining unconscious. Rather, the GCSE of the patients
requiring anesthesia to BS seems to be more aggressive than
that of the non-BS-group.
No previous studies have focused on the association of BS
to the ending of the GCSE or to return of consciousness. We
found a significant correlation between early obtainment of
BS and early return of consciousness. In our study, the delays
in achieving BS did not reach the time frames recommended
in the guidelines, reflecting the clinical reality. At least the
anesthesia-to-BS delay could be dramatically shortened with
an accurate management protocol, as shown in two prospec-
tive studies [42, 43]. Since nearly half of our patients seemed
to benefit from early BS, the question remains, whether the
third-stage treatment given up to BS level in recommended
time frames would increase the proportion of patients
returning of consciousness also among severe GCSE cases.
In parallel, one previous study has speculated that possibly
treatment delay is critical for extremely severe SE episodes,
although not for all types of SE [20].
We found a significant correlation between early clinical
seizure freedom and early return of consciousness. These
results are in accordance with the previous literature showing
the impact of seizure freedom on prognosis. Claassen et al.
found that the delayed seizure control has a negative effect
on the efficacy of treatment and that it increases mortality
[40]. It has also been stated that the longer the duration of SE
the worse the prognosis, particularly after 1-2 h of continuous
seizures. It has been claimed that this relation may be lost,
if SE lasts over 10 h [36]. However, in our material the mean
delay of clinical seizure freedom, although being over 31 h,
still correlated with the return of consciousness and thus
predicted the cessation of GCSE.
To our surprise onset-to-initial-treatment time, onset-to-
diagnosis time, and onset-to-anesthesia timedid not correlate
to markers for cessation of GCSE. There are no other studies
on the effect of diagnosis- and anesthesia-related delays on
duration of GCSE in adult patients. There is evidence from a
pediatric study suggesting that prehospital diazepam short-
ens the duration of SE [44]. On the other hand, we have
previously shown that short initial treatment delay per se does
not lead to a better treatment response delay, unless the whole
prehospital treatment chain functions optimally [24].
Regression analysis showed that prolonged time between
initial treatment and second-stage treatment predicts a
delayed clinical seizure freedom and return of consciousness.
Also the time between initial treatment and diagnosis may
affect the delay to clinical seizure freedom.Thus, it is feasible
that a failure or slow-up in any single delay component may
ravage the benefits acquired by optimal action of the earlier
phases of the treatment chain.
4.2. Relation of Prognostic Factors to Cessation of GCSE. Prog-
nostic factors of SE have been studied in detail, and in most
reports the main focus has been on outcome, defined as
mortality or clinical status at discharge. To our knowledge,
there are no studies on the relation of prognostic factors to
cessation of GCSE.
There is a consensus in literature that old age, defined in
most studies as the age over 65 years, correlates with worse
outcome [21, 36, 45–50]. Significance of age is partly based on
pediatric studies, in which age was the major determinant of
prognosis, in contrast to adult SE [36]. Prehospital delays in
adults do not differ significantly between age groups, when
the cutoff point is set at 65 years [24]. In the present study,
we did not find any correlation between age and markers for
cessation of GCSE. Neither were differences in probability
of returning consciousness found between age groups. Our
results thus support the previous conclusion that higher
mortality of old SE patients may be due to higher frequency
of treatment complications [16, 22]. A rational conclusion is
that quickly administered second-stage medication should
improve the prognosis of GCSE in elderly patients by less-
ening the need for ICU treatment.
The SE episodes in epilepsy-related cases are commonly
thought to be easier to treat, and their outcome is in most
studies found to be better than that of patients presenting
acute symptomatic seizures [7, 21, 33]. The absence of pre-
vious seizures implicates that acute symptomatic seizure as
such may be used as a prognostic marker [21]. The delays in
the treatment of SE patients with known epilepsy in the pre-
hospitalmanagement are shorter than those of the nonepilep-
tic patients. Moreover, epilepsy patients are more likely to be
triaged directly to tertiary hospital, diagnosed with SE and
anesthetized earlier than nonepileptic patients [24]. Surpris-
ingly, this advantage of shorter delays does not seem to be
beneficial to epilepsy patients, suggested by our finding that
previously diagnosed epilepsy does not predict faster cessa-
tion ofGCSE or higher likelihood of returning consciousness.
STESS is an internally and externally validated tool for
systematic evaluation of the outcome of SE patients and
may be used to recognize the patients who need aggressive
treatment [21, 51]. Its scoring criteria include established
variables, which all are proven to affect the outcome [21].
However, the cutoff-point for poor outcome is subject to
debate [21, 22, 51]. We found no correlation between STESS
points andmarkers for cessation ofGCSEwith any cutoff.Nor
did any STESS point cutoff predict return of consciousness.
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This is in line with the present observation that two of the
STESS variables, age and previous epilepsy diagnosis, lacked
correlation with cessation of SE. Taken together, the cessation
of GCSE may be more dependent on the management of
GCSE than the initial severity of SE.
As can be expected by definition, SRSE cases showed
longer delays of clinical seizure freedom and return of con-
sciousness than RSE and non-RSE cases. Interestingly, the
delay of obtaining BS did not predict development of SRSE.
4.3. Relation of Other Factors to Cessation of GCSE. In our
material, the response to first line treatment neither corre-
lated with any of the markers for cessation of GCSE nor
predicted return of consciousness. This may be due to the
fact that our material included relatively large number of
RSE cases, possibly because SE cases successfully treated
with first-stage medication were not referred to the tertiary
hospital. A recent study reported that the efficacy of the first-
stage treatment does not affect the duration of SE [52], while
another study presented an opposite result [35].
Pre-SE period, that is, occurrence of recurring convulsive
seizures preceding the actual SE, is a newly introduced con-
cept [12], the significance of which has not yet been estab-
lished. In the present study, pre-SE period did not correlate
with the delay in cessation of SE. We did not find any sig-
nificant correlation between the type of SE onset and return
of consciousness.
5. Conclusions
We conclude that early administration of second-stage medi-
cation, early cessation of clinical seizures, and early obtain-
ment of BS predict early return of consciousness, which is
an unambiguous marker for the cessation of SE. The present
retrospective study suggests that delays in treatment chain
may bemore significant determinants of SE cessation than the
previously established outcome predictors. The correlations
presented here serve as validation for the use of stepwise
definition of the end of SE and speak for consideration of BS
as the target of the third-stage treatment. The delays should
also be considered in planning protocols, particularly in
matching of patient groups, in prospective SE studies.
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